NASDAQ:KRBP Kiromic BioPharma (KRBP) Stock Price, News & Analysis $1.79 -0.26 (-12.68%) (As of 07/25/2024 ET) Add Compare Share Share Today's Range$1.79▼$1.9550-Day Range$1.75▼$3.2952-Week Range$0.16▼$3.78Volume3,374 shsAverage Volume3,865 shsMarket Capitalization$2.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends Get Kiromic BioPharma alerts: Email Address Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Kiromic BioPharma Stock (NASDAQ:KRBP)Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Read More KRBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRBP Stock News HeadlinesJuly 20, 2024 | finance.yahoo.comKiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion PhaseJune 20, 2024 | businesswire.comKiromic BioPharma Provides Updates on its Deltacel-01 Clinical TrialJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! June 6, 2024 | businesswire.comKiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical TrialMay 29, 2024 | markets.businessinsider.comKiromic BioPharma's Deltacel-01 Phase 1 Trial Shows Early Efficacy At Sixth WeekMay 29, 2024 | businesswire.comKiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical TrialMay 20, 2024 | businesswire.comKiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial SiteMay 13, 2024 | investorplace.comKRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! April 26, 2024 | uk.investing.comDeltacel shows promise in Kiromic BioPharma lung cancer trial, Kiromic seeks FDA fast trackApril 24, 2024 | finance.yahoo.comKiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three PatientsApril 10, 2024 | msn.comKiromic BioPharma files to withdraw registration statementApril 2, 2024 | businesswire.comKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical TrialMarch 19, 2024 | finance.yahoo.comEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical TrialMarch 19, 2024 | businesswire.comEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical TrialMarch 1, 2024 | businesswire.comKiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialFebruary 28, 2024 | finance.yahoo.comKiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7thFebruary 28, 2024 | businesswire.comKiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7thSee More Headlines Receive KRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRBP CUSIPN/A CIK1792581 Webwww.kiromic.com Phone832-968-4888FaxN/AEmployees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,950,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-133.33% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.25) per share Price / Book-0.25Miscellaneous Outstanding Shares1,550,000Free Float1,228,000Market Cap$2.77 million OptionableNot Optionable Beta1.96 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Pietro Bersani CPA (Age 56)J.D., CEO & Director Comp: $891.69kMr. Brian Hungerford (Age 48)Chief Financial Officer Comp: $160.69kDr. Leonardo Mirandola Ph.D. (Age 42)Chief Scientific Officer & Interim COO Comp: $383.32kDr. Scott Dahlbeck M.D. (Age 62)Pharm.D., PharmD, Chief of Staff Comp: $359.08kKey CompetitorsImunonNASDAQ:IMNNCardio DiagnosticsNASDAQ:CDIOEterna TherapeuticsNASDAQ:ERNAPHAXIAM TherapeuticsNASDAQ:PHXMRedHill BiopharmaNASDAQ:RDHLView All Competitors KRBP Stock Analysis - Frequently Asked Questions How have KRBP shares performed this year? Kiromic BioPharma's stock was trading at $0.87 at the start of the year. Since then, KRBP shares have increased by 105.7% and is now trading at $1.79. View the best growth stocks for 2024 here. How were Kiromic BioPharma's earnings last quarter? Kiromic BioPharma, Inc. (NASDAQ:KRBP) announced its quarterly earnings results on Friday, May, 10th. The company reported ($1.00) EPS for the quarter. When did Kiromic BioPharma's stock split? Kiromic BioPharma shares reverse split before market open on Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Kiromic BioPharma IPO? Kiromic BioPharma (KRBP) raised $16 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 1,200,000 shares at a price of $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager. How do I buy shares of Kiromic BioPharma? Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRBP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiromic BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.